IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Increased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 54,792 shares of the company’s stock after buying an additional 572 shares during the period. DekaBank Deutsche Girozentrale’s holdings in IDEXX Laboratories were worth $27,892,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter valued at about $26,000. Ridgewood Investments LLC acquired a new stake in IDEXX Laboratories during the second quarter valued at approximately $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories during the second quarter worth approximately $28,000. Mowery & Schoenfeld Wealth Management LLC grew its position in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of IDEXX Laboratories in the second quarter valued at $36,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $449.44 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The company has a market capitalization of $37.12 billion, a price-to-earnings ratio of 43.51, a P/E/G ratio of 4.03 and a beta of 1.33. The business’s 50-day moving average is $483.67 and its 200-day moving average is $488.84. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company earned $2.67 EPS. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the subject of several research reports. BTIG Research began coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.